HRMY | Ticker Profile - Titan Protect

HRMY

Harmony Biosciences Holdings, Inc.

Healthcare · Biotechnology · NGM

$32.20

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.8B

Total market value of the company

Trailing P/E

12.40

Reasonably valued

Forward P/E

5.51

Based on estimated future earnings — lower means cheaper

Rev Growth

+16.6%

Year-over-year revenue change

Profit Margin

16.2%

How much profit the company keeps from each dollar of revenue

ROE

17.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$43.00

+34% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 11 analysts covering this stock

About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

https://www.harmonybiosciences.com

Country: United States Employees: 293 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.307

Positive but modest risk-adjusted returns

Kelly Fraction

0.0129

Marginal edge — very small allocation suggested

Calmar Ratio

0.097

Drawdown risk outweighs the returns — higher risk profile

Annual Return

3.6%

Historical annualised return based on price data

Max Drawdown

-37.6%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.97

Less volatile than the market — more defensive

52W High

$40.87

21% below the year high

52W Low

$25.52

26% above the year low

Avg Volume

779,349

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

15.3%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$2.48

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

18.08

Heavy leverage — higher financial risk if revenues decline

Current Ratio

3.58

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

3.45

Like current ratio but excludes inventory — stricter test

Gross Margin

76.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

17.3%

Profit from core operations before interest and tax

Free Cash Flow

$150M

Positive — the business generates more cash than it spends

Revenue (TTM)

$899M

Total revenue over the last 12 months

Net Income

$146M

Profitable — the bottom line is positive

Analyst Coverage

Analysts

Target High

$85.00

Target Median

$43.00

Target Low

$28.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go